Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

CMS Proposes Payment Changes For Home Health Services To Protect Beneficiaries And Medicare
The Centers for Medicare & Medicaid Services (CMS) announced a proposed 2.2 percent home health market basket update to the home health prospective payment system (HH PPS) rates for calendar year (CY) 2010. Also, as part of ongoing efforts to address potential fraud and abuse with regards to outlier payments under the HH PPS, CMS is proposing modifications to its outlier policy.
generic viagra online
WHO Calls For Images Of Smoking-Related Diseases On Cigarette Packaging
In an effort to increase the public"s awareness of the health consequences of cigarettes, the WHO on Friday called on international governments to require that cigarette packages feature images of the harmful effects smoking can have on the body, the AP/Google.com reports (Klapper, AP/Google.com, 5/29). Drugshop to buy zoloft online and other pills.
News of the day
New Data: Efficacy And Responder Analyses Of Divigel(R) (estradiol Gel) 0.1 Percent For The Treatment Of Menopause
Upsher-Smith Laboratories, Inc. presented the results of a secondary analysis to determine the response rates to three doses of transdermal Divigel(R) (estradiol gel) 0.1 percent at the recent 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) in Chicago. The objectives of this secondary analysis of a phase III efficacy trial were to determine the percent of postmenopausal women who achieved a greater than 50 percent reduction in the frequency of moderate to severe vasomotor symptoms (MSVMS), or hot flashes, and to assess the change from baseline in a quality of life (Kupperman) index score that evaluated various menopausal symptoms. Divigel(R) doses studied included 1.0 mg, 0.5 mg and 0.25 mg of estradiol/day - the lowest effective approved dose of estradiol available for the treatment of MSVMS. The analysis showed a significantly greater percentage of women in all treatment groups versus placebo experienced > / = 50 percent reduction in the frequency of MSVMS at week 12. In the Divigel(R) 1.0 mg estradiol/day dosing group, 90 percent of women reported at least a 50 percent reduction in the frequency of MSVMS. Additionally, at 12 weeks, each of the doses of Divigel(R) significantly reduced the severity of menopausal symptoms identified by a quality of life index score compared to placebo.
Endocrinology

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HYLATOPIC™ Emollient Foam is formulated to rapidly hydrate the stratum corneum, the top layer of the skin, and immediately provide a semi-permeable barrier that protects against irritants and excessive water loss through the epidermis. HYLATOPIC™ is clinically proven to rapidly increase skin hydration and reduce transepidermal water loss1, supporting the skin"s natural recovery from skin barrier dysfunction to optimize therapeutic outcomes. HYLATOPIC™ is safe and easy to spread over large areas and therefore is ideal for atopic dermatitis patients with disease coverage on greater than 10% body surface area (BSA). The Company"s recent market research with dermatologists indicates that 70% or more of their patients may have atopic dermatitis present on at least 10% of their body. Developed with the Company"s DELEVO™ Foam Technology, HYLATOPIC™ is cosmetically elegant, contains no drying alcohols, is absorbed rapidly, and leaves no oily or sticky residue. "We are very excited to be able to offer HYLATOPIC™ to our physicians and patients," states Michael Heffernan, President of Onset Therapeutics. "It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. HYLATOPIC"s 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes." HYLATOPIC™ Emollient Foam is currently available through all major drug wholesalers. About Atopic Dermatitis Atopic dermatitis is a disease characterized by dry, cracked, itchy, and inflamed skin, often presenting on greater than 10% of the body surface area. It accounts for 10-20% of all Dermatology visits2 and affects approximately 3% of the US population2, 90% of whom develop symptoms by age 53. The compromised skin barrier in atopic dermatitis patients allows excessive water loss through the epidermal layer of the skin and penetration of potential allergens. About Onset Therapeutics Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the Company"s innovative proprietary topical formulation technologies and unique delivery systems. The Company utilizes its novel DELEVO™ Foam Technology that is designed to deliver enhanced penetration of proven active ingredients in cosmetically elegant, hydrating formulations with the goal of enhancing patient compliance. For more information, please visit the company"s website at http://www.onsettx.com. References: 1. Data on File Collegium Pharmaceutical 2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: http://www.niams.nih.gov/hi/topics/dermatitis/index.html. 3. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721. Onset Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009